Citadel Advisors
AVXL icon

Citadel Advisors’s Anavex Life Sciences AVXL Stock Holding History

Citadel Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.7M Sell
553,400
-153,900
-22% -$667K ﹤0.01% 6450
2025
Q4 		$2.52M Buy
707,300
+316,200
+81% +$1.94M ﹤0.01% 5495
2025
Q3 		$3.48M Buy
391,100
+96,700
+33% +$981K ﹤0.01% 5023
2025
Q2 		$2.71M Sell
294,400
-25,100
-8% -$214K ﹤0.01% 5145
2025
Q1 		$2.74M Sell
319,500
-53,000
-14% -$500K ﹤0.01% 4927
2024
Q4 		$4M Buy
372,500
+105,600
+40% +$812K ﹤0.01% 4335
2024
Q3 		$1.52M Buy
266,900
+29,400
+12% +$170K ﹤0.01% 6030
2024
Q2 		$1M Sell
237,500
-131,600
-36% -$532K ﹤0.01% 6572
2024
Q1 		$1.88M Buy
369,100
+87,300
+31% +$491K ﹤0.01% 5650
2023
Q4 		$2.62M Buy
281,800
+111,600
+66% +$768K ﹤0.01% 4886
2023
Q3 		$1.11M Sell
170,200
-2,400
-1% -$19.1K ﹤0.01% 6338
2023
Q2 		$1.4M Sell
172,600
-273,700
-61% -$2.35M ﹤0.01% 5791
2023
Q1 		$3.82M Buy
446,300
+26,500
+6% +$264K ﹤0.01% 4254
2022
Q4 		$3.89M Buy
419,800
+219,300
+109% +$2.34M ﹤0.01% 4289
2022
Q3 		$2.07M Buy
200,500
+66,700
+50% +$704K ﹤0.01% 5531
2022
Q2 		$1.34M Sell
133,800
-25,000
-16% -$237K ﹤0.01% 6374
2022
Q1 		$1.96M Sell
158,800
-100
-0.1% -$1.23K ﹤0.01% 6129
2021
Q4 		$2.75M Sell
158,900
-75,100
-32% -$1.43M ﹤0.01% 5505
2021
Q3 		$4.2M Sell
234,000
-44,300
-16% -$882K ﹤0.01% 4639
2021
Q2 		$6.36M Buy
278,300
+179,100
+181% +$2.65M ﹤0.01% 3935
2021
Q1 		$1.48M Buy
99,200
+53,500
+117% +$584K ﹤0.01% 7132
2020
Q4 		$247K Sell
45,700
-14,400
-24% -$75.9K ﹤0.01% 9414
2020
Q3 		$273K Sell
60,100
-3,500
-6% -$15.1K ﹤0.01% 8283
2020
Q2 		$313K Buy
63,600
+38,700
+155% +$146K ﹤0.01% 7841
2020
Q1 		$78K Buy
24,900
+14,300
+135% +$49.8K ﹤0.01% 8799
2019
Q4 		$27K Buy
+10,600
New +$27.8K ﹤0.01% 8891
2019
Q3 		– Sell
-12,000
Closed -$40K – 9139
2019
Q2 		$40K Sell
12,000
-4,700
-28% -$14.6K ﹤0.01% 8797
2019
Q1 		$51K Buy
16,700
+3,000
+22% +$7.17K ﹤0.01% 8808
2018
Q4 		$21K Sell
13,700
-2,400
-15% -$5.45K ﹤0.01% 8729
2018
Q3 		$44K Sell
16,100
-5,500
-25% -$15.5K ﹤0.01% 8826
2018
Q2 		$57K Buy
21,600
+3,000
+16% +$8.38K ﹤0.01% 8412
2018
Q1 		$51K Sell
18,600
-13,300
-42% -$37.6K ﹤0.01% 7920
2017
Q4 		$103K Buy
31,900
+19,400
+155% +$76.4K ﹤0.01% 7418
2017
Q3 		$52K Sell
12,500
-9,100
-42% -$40.4K ﹤0.01% 7178
2017
Q2 		$115K Sell
21,600
-8,100
-27% -$46.8K ﹤0.01% 6858
2017
Q1 		$170K Buy
29,700
+16,400
+123% +$84.7K ﹤0.01% 6630
2016
Q4 		$53K Sell
13,300
-25,300
-66% -$90.1K ﹤0.01% 6854
2016
Q3 		$140K Buy
38,600
+7,100
+23% +$29.9K ﹤0.01% 6512
2016
Q2 		$192K Buy
31,500
+19,500
+163% +$94.2K ﹤0.01% 5867
2016
Q1 		$59K Sell
12,000
-10,700
-47% -$47.1K ﹤0.01% 6208
2015
Q4 		$126K Buy
+22,700
New +$162K ﹤0.01% 6424

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Citadel Advisors's AVXL Position: Q1 2026 in Review

Citadel Advisors increased its Anavex Life Sciences (AVXL) stake by 392% in Q1 2026, buying an estimated $1.93M and bringing the position to 559,435 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #6419.

Citadel Advisors first reported a position in AVXL in Q4 2015 and has held it in 36 quarters since. The position peaked at $7M in Q2 2022. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

  • Citadel Advisors held 559,435 shares of Anavex Life Sciences worth $1.72M as of Q1 2026.
  • Citadel Advisors bought 445,696 Anavex Life Sciences shares in Q1 2026, an estimated $1.93M.
  • Anavex Life Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6419 holding.
  • Citadel Advisors first reported a position in Anavex Life Sciences in Q4 2015 and has held it in 36 quarters since.
  • Citadel Advisors's Anavex Life Sciences position peaked at $7M in Q2 2022.
  • 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.